WeedStreet420
  • Newsletter
  • Colors
    Light Theme Dark Theme
    Screen options
    Full Screen Mode Boxed Layout Mode
    • Watch List
      • Daily Top Gainers
      • Daily Top Losers
      • 52-Weeks Highs
      • Most Volume
    • Psychedelics Companies List
    • TOP PICKS
    • Press Releases
    • News
      • All News
      • Shroom Stocks News
      • Science & Studies
      • Legislation News
    • Heat Map
    • Calendar
  • Watch List
    • Daily Top Gainers
    • Daily Top Losers
    • 52-Weeks Highs
    • Most Volume
  • Psychedelics Companies List
  • TOP PICKS
  • Press Releases
  • News
    • All News
    • Shroom Stocks News
    • Science & Studies
    • Legislation News
  • Heat Map
  • Calendar
WeedStreet420

SUBSCRIBE NOW

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

375 views2 min read

Silo Pharma Provides Details of Patent License Agreement for Psilocybin and Cancer Applications

Silo PharmaJanuary 11, 2021 -

Englewood Cliffs, NJ, Jan. 11, 2021 — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, last week announced a licensing agreement with up-front payment valued at $1 Million.  The license agreement (the “Agreement”) with Aikido Pharma Inc., (Nasdaq:AIKI) a listed biotechnology company, grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer.

In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed.


  Subscribe to news from
Silo Pharma

Be the first to know when breaking news are released.



“Our Agreement advances Silo Pharma’s unique approach to researching and discovering therapeutics that can be used in combination with psychedelic elements” stated Eric Weisblum, Chairman and CEO of Silo Pharma Inc. “We are enthusiastic about this agreement and opportunity.  Researching the use of psilocybin to treat both cancer and cancer side effects is a noteworthy opportunity for Silo Pharma and its shareholders. We look forward to updating investors on this agreement and further developments.”

Further information regarding the Agreement can be found in the Company’s Form 8-K filed with the SEC on January 11, 2021.

About Silo Pharma

Silo Pharma is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Company Contact: Investor Relations Contact: 
Silo Pharma, Inc.
Eric Weisblum, CEO

Email: [email protected]

Hayden IR
Brett Maas
646-536-7331
Email: [email protected]

  • Share on Twitter
  • Facebook
  • Reddit
  • LinkedIn

SILOSilo Pharma Inc.





More news from Silo Pharma

  • Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

    Silo PharmaJuly 27, 2022 -
  • Silo Pharma Announces Positive Results in Subcutaneous Delivery of its Novel Liposomes to Treat Arthritic Patients

    Silo PharmaJuly 12, 2022 -
  • Silo Pharma Expands License Agreement and Patent Portfolio

    Silo PharmaJune 23, 2022 -
  • Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson’s Disease in Psilocybin Study

    Silo PharmaMay 19, 2022 -
  • Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

    Silo PharmaApril 20, 2022 -
  • Silo Pharma Enters into Agreement with Contract Research Organization for Pharmacokinetic Study

    Silo PharmaMarch 31, 2022 -

View Watch List (65 companies)

POPULAR

Delic Announces Two Key Executive Appointments

25 Views

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

22 Views

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

21 Views

Field Trip Health & Wellness Ltd. Provides Update on TSX Venture Exchange Listing

20 Views

Pure Extracts Delivers Its Largest Shipments to Launch its Newest Vape Product

16 Views

Field Trip Health & Wellness Ltd. to Commence Trading on the TSX Venture Exchange on August 17, 2022

12 Views

Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements

8 Views

Bright Minds Biosciences Comments on Recent Trading Activity

5 Views

RECENT

Aion Therapeutic Reports Delay in Filing 2022 Annual Financial Statements

0 Views

Bright Minds Biosciences Comments on Recent Trading Activity

0 Views

Pure Extracts Delivers Its Largest Shipments to Launch its Newest Vape Product

0 Views

Health Canada Grants MDMA Production and Distribution Amendment to Optimi Health

0 Views

Field Trip Health & Wellness Ltd. to Commence Trading on the TSX Venture Exchange on August 17, 2022

0 Views

Delic Announces Two Key Executive Appointments

0 Views

Mydecine Reports Financial Results for the Second Quarter of Fiscal Year 2022

0 Views

Field Trip Health & Wellness Ltd. Provides Update on TSX Venture Exchange Listing

0 Views

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

0 Views

Optimi Health Unveils Canada’s First Natural Therapeutic Psilocybin Product For Approved Patients

0 Views





Make smarter investment strategies
with in-depth news reports

Join our subscribers!

By subscribing, you agree to our Terms and Conditions
We don't spam and we promise to never share your information.

Risk Warning
Privacy Policy
Methodology
Disclaimer
Contact Us
Advertising
© 2022 Shroom Investor 🍄 is a subsidiary of Upside Makers inc.   By using this website, you agree to our Terms of Use